LMM results. (A) Effect displays. Treatments are on the x-axis. Dots represent the fixed effect coefficients of %ΔV on log scale estimated by the LMM. The bars are the 95% CIs of fixed effect coefficients. (B) Post-hoc test results. Differences of marginal means are on the x-axis and pairwise comparisons between treatments are displayed on the y-axis. Blue bars represent the 95% CIs of marginal means differences estimated through R package emmeans. The dashed line corresponds to a difference of zero between means.

Error bars represent 95% confidence intervals of the %∆V calculated using random-effects model. Subgroup analyses for the treatment efficacy of 5-FU (A), FOLFOX (B), FOLFIRI (C), and FOLFOXIRI (D), with respect to each patient control were also conducted. Green 95% confidence intervals represent a statistically significant difference to the control.

Clustering of colorectal cancer patients according to k-means and principal component analysis.

Error bars represented 95% confidence interval of the %∆V for 5-FU (A), FOLFOX (B), FOLFIRI (C), and FOLFOXIRI (D) resulted from k-means clustering. The graphs displayed how patients within each chemotherapy treatment were assigned in one of the five cluster groups. The different colors identified different clusters.

Percentage of progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR). 5-FU, FOLFOX, FOLFIRI and FOLFOXIRI treatments in zebrafish avatars xenotransplanted with colorectal tumor (n = 36 patient samples analyzed).

Comparison of the follow-up data with the predicting outcome of the zPDX. PR: partial response, SD: stable disease; PD: progression disease. Capecitabine was orally administered to Patient C038, whereas 5-FU was tested in its zPDX.